Aggressive Breast Cancer Responds to New Drug

In the clinical trial of the new drug, sacituzumab govitecan, about a third of the patients responded to treatment and the effect lasted up to eight months. The research was funded by the drug's maker.

from WebMD Health webmd

If You Enjoyed This, Take 5 Seconds To Share It

• 
• 
• 
• 
• 
•